XML 51 R31.htm IDEA: XBRL DOCUMENT
v3.20.4

License and Collaboration Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Summary of Revenues by Collaboration and by Category of Revenue | The following table summarizes details of revenues by collaboration and by category of revenue:
|  |  | Year Ended December 31, |
Revenues recognized: | Over time | Point in time | 2020 |  |  | 2019 |  |  | 2018 |
Gilead license to zimberelimab |  | * | $ | 55,096 |  |  | $ | - |  |  | $ | - |
Gilead access rights related to the Company's research and development pipeline | * |  |  | 15,421 |  |  |  | - |  |  |  | - |
Taiho license to zimberelimab |  | * |  | - |  |  |  | 8,000 |  |  |  | - |
Taiho license to etrumadenant |  | * |  | - |  |  |  | - |  |  |  | 3,000 |
Taiho collaboration agreement | * |  |  | 7,000 |  |  |  | 7,000 |  |  |  | 5,353 |
Total collaboration and license revenue |  |  | $ | 77,517 |  |  | $ | 15,000 |  |  | $ | 8,353 |
Summary of Revenue Recognized as a Result of Changes in Deferred Revenue | The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):
|  |  | Year Ended December 31, |
Revenue recognized in the period from: |  |  | 2020 |  |  | 2019 |  |  | 2018 |
Amounts included in deferred revenue at the beginning of the period |  |  | $ | 7,000 |  |  | $ | 7,000 |  |  | $ | 5,353 |
Performance obligations satisfied in previous period |  |  |  | - |  |  |  | - |  |  |  | - |
Schedule of Payments Allocated to Performance Obligations | At the transaction closing date, these payments were allocated to the performance obligations identified as follows:
|  |  |  | Amount |
Allocation of transaction price |  |  |  |  |  |
Upfront cash consideration |  |  |  | $ | 175,000 |
Payment for access rights related to the Company's research and development pipeline |  |  |  |  | 100,000 |
Premium from Stock Purchase Agreement |  |  |  |  | 90,600 |
Total transaction price allocated to revenue |  |  |  | $ | 365,600 |
Allocation to performance obligations |  |  |  |  |  |
Zimberelimab license |  |  |  | $ | 55,096 |
Etrumadenant option |  |  |  |  | 126,960 |
Domvanalimab option |  |  |  |  | 36,728 |
Access rights related to the Company's research and development pipeline |  |  |  |  | 137,113 |
Development and commercialization services for zimberelimab |  |  |  |  | 9,703 |
Total |  |  |  | $ | 365,600 |
Gilead and Taiho |
Summary of Revenues | The following table summarizes the revenues received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):
|  |  | Year Ended December 31, |
|  |  | 2020 |  |  | 2019 |  |  | 2018 |
License revenue |  |  | $ | 55,096 |  |  | $ | 8,000 |  |  | $ | 3,000 |
Collaboration revenue |  |  |  | 22,421 |  |  |  | 7,000 |  |  |  | 5,353 |
Collaboration and license revenue |  |  | $ | 77,517 |  |  | $ | 15,000 |  |  | $ | 8,353 |

X
- Definition Schedule of payments allocated to performance obligations. + References No definition available. + Details
Name: | rcus_ScheduleOfPaymentsAllocatedToPerformanceObligationsTableTextBlock
Namespace Prefix: | rcus_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of revenues. + References No definition available. + Details
Name: | rcus_SummaryOfRevenuesTableTextBlock
Namespace Prefix: | rcus_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GileadSciencesIncAndTaihoPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |